Akeso begins Phase 3 trial of cadonilimab as consolidation therapy for non-small cell lung cancer
Akeso, Inc. (9926.HK) has initiated its pivotal Phase 3 cadonilimab trial for non-small cell lung cancer (NSCLC), marking a significant advancement in immunotherapy research. The ... Read More
ImmunityBio, BeiGene launch Phase 3 Trial to advance lung cancer immunotherapy
ImmunityBio, Inc. (NASDAQ: IBRX) has entered into a collaboration and supply agreement with BeiGene, Ltd., a global oncology company, to initiate a confirmatory Phase 3 ... Read More
FDA approves Bristol Myers Squibb’s Opdivo for expanded lung cancer treatment, boosting stock and investor sentiment
In a significant step forward for lung cancer treatment, the US Food and Drug Administration (FDA) has expanded its approval of Bristol Myers Squibb's Opdivo ... Read More
AstraZeneca’s breakthrough in lung cancer treatment: Datopotamab deruxtecan achieves promising survival rates
AstraZeneca's datopotamab deruxtecan (Dato-DXd), a cutting-edge TROP2-directed antibody-drug conjugate, has demonstrated encouraging overall survival results in the TROPION-Lung01 Phase III trial, which focused on patients ... Read More
FDA approves RYBREVANT and LAZCLUZE for EGFR-mutated advanced lung cancer
The U.S. Food and Drug Administration (FDA) has approved the combination of RYBREVANT (amivantamab-vmjw) and LAZCLUZE (lazertinib) as a first-line therapy for adults with advanced ... Read More
Tempus and AstraZeneca expand collaboration to enhance cancer care with AI
Tempus, a pioneer in artificial intelligence and precision medicine, has announced an expansion of its collaboration with pharmaceutical giant AstraZeneca. This enhanced partnership focuses on ... Read More
Dizal’s sunvozertinib shows promising results in global pivotal lung cancer study
Dizal, a prominent biopharmaceutical company listed on the Shanghai Stock Exchange (SSE:688192), has announced significant clinical results from its WU-KONG1 Part B (WU-KONG1B) study of ... Read More
Setback for Bristol Myers Squibb: CheckMate -73L trial fails to meet endpoint
Bristol Myers Squibb (NYSE: BMY) announced that its Phase 3 CheckMate -73L trial did not achieve its primary endpoint of progression-free survival (PFS) in patients ... Read More
Bristol Myers Squibb announces success of KRAZATI in Phase 3 KRYSTAL-12 study
Bristol Myers Squibb (NYSE: BMY) has reached a pivotal milestone in the treatment of non-small cell lung cancer (NSCLC) with its announcement regarding the KRYSTAL-12 ... Read More
InnoCare Pharma, ArriVent BioPharma initiate Phase 1b clinical trial in NSCLC
InnoCare Pharma, listed on both the Hong Kong Stock Exchange (HKEX: 09969) and the Shanghai Stock Exchange (SSE: 688428), along with ArriVent BioPharma, Inc. (Nasdaq: ... Read More